# Launch prices indexed to the ESMO benefit scale, revisited when survival matures

Source: https://onco.cc/ideas/idea-fund-mcbs-linked-pricing/  
OnCo record `idea-fund-mcbs-linked-pricing` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Pay more for drugs that clearly help people live longer or better, and less for those that barely move the needle, using a public benefit scale doctors already use.

## Summary

National payers adopt a rule that reimbursed price at launch is tied to the ESMO Magnitude of Clinical Benefit Scale (or ASCO Value Framework) grade of the pivotal evidence, with a mandatory renegotiation when overall survival or quality-of-life data mature. Grade 4 to 5 (or A to B in curative settings) commands a premium band; grade 1 to 2 is reimbursed only at or near the price of the comparator. Several European payers already consult the scale informally; making the link explicit and automatic changes the return calculus for marginal drugs before they enter development.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Explicit MCBS-indexed pricing across a group of countries lowers the average launch price of low-benefit oncology drugs by at least 30% and, within eight years, increases the proportion of pivotal trials designed to achieve high MCBS grades (overall survival, quality of life endpoints).
- Rationale: Value-based frameworks exist and are validated but have no teeth; where price is linked to benefit (Germany's AMNOG added-benefit assessment, France's ASMR rating) evidence of a shift in development priorities has been reported. Oncology has the best-developed benefit scales of any specialty.
- Proposed test: A payer coalition applies the rule to all new oncology reimbursements for three years and compares launch prices and pivotal trial designs of subsequent filings with a control set of countries.
- Maturity: speculative
- Actor: payer

## Sources

- ESMO Magnitude of Clinical Benefit Scale: https://www.esmo.org/guidelines/esmo-mcbs

## Connected records

- ideas: [Outcome-based annuity payments for potentially curative one-time therapies](https://onco.cc/ideas/idea-fund-pay-for-cure-annuities/), [Patent term extension scaled to proven survival gain](https://onco.cc/ideas/idea-fund-value-based-patent-extension/)
- institutions: [American Society of Clinical Oncology (ASCO)](https://onco.cc/institutions/asco/), [European Society for Medical Oncology (ESMO)](https://onco.cc/institutions/esmo/)
- terms: [Overall survival (OS)](https://onco.cc/terms/os/), [Progression-free survival (PFS)](https://onco.cc/terms/pfs/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-mcbs-linked-pricing.json